1. Home
  2. CTXR vs VNRX Comparison

CTXR vs VNRX Comparison

Compare CTXR & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.65

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Logo VolitionRX Limited

VNRX

VolitionRX Limited

BUY

Current Price

$2.71

Market Cap

22.5M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CTXR
VNRX
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
22.5M
IPO Year
2010
2012

Fundamental Metrics

Financial Performance
Metric
CTXR
VNRX
Price
$0.65
$2.71
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$6.00
$1.67
AVG Volume (30 Days)
696.7K
3.0M
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
43.38
38.00
EPS
N/A
N/A
Revenue
N/A
$1,727,384.00
Revenue This Year
N/A
$355.66
Revenue Next Year
$147.57
$849.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
40.04
52 Week Low
$0.63
$0.13
52 Week High
$2.38
$0.94

Technical Indicators

Market Signals
Indicator
CTXR
VNRX
Relative Strength Index (RSI) 37.33 97.58
Support Level N/A $0.20
Resistance Level $0.98 N/A
Average True Range (ATR) 0.07 0.03
MACD -0.02 0.16
Stochastic Oscillator 5.97 97.77

Price Performance

Historical Comparison
CTXR
VNRX

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

Share on Social Networks: